Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV : Results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age

Autor: Franco Maggiolo, Giuliano Rizzardini, Jean‐Michel Molina, Federico Pulido, Stephane De Wit, Linos Vandekerckhove, Juan Berenguer, Michelle L. D'Antoni, Christiana Blair, Susan K. Chuck, David Piontkowsky, Hal Martin, Richard Haubrich, Ian R. McNicholl, Joel Gallant

Publikováno v: HIV MEDICINE

Objectives Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is an effective treatment for HIV-1 infection; however, clinical trial data in older people living with HIV (PLWH) are lacking. The primary 24-week and secondary 48-week analyses of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::448270fda82fa1b915c7c1fffa58ef73
https://doi.org/10.1111/hiv.13319

Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial

Autor: Onyema Ogbuagu, Peter J Ruane, Daniel Podzamczer, Laura C Salazar, Keith Henry, David M Asmuth, David Wohl, Richard Gilson, Yongwu Shao, Ramin Ebrahimi, Stephanie Cox, Alexander Kintu, Christoph Carter, Moupali Das, Jared M Baeten, Diana M Brainard, Gary Whitlock, Jason M Brunetta, Gitte Kronborg, Christoph D Spinner, Andrea Antinori, Vanessa Apea, David Asmuth, Ann Avery, Paul Benson, Colm Bergin, Mezgebe Berhe, Indira Brar, Cynthia Brinson, Jason Brunetta, Jeffrey Burack, Thomas Campbell, Michelle Cespedes, Amanda Clarke, Megan Coleman, Josep Coll, Manuel Crespo Casal, Catherine Creticos, Gordon Crofoot, Frederick Cruickshank, Eric Cua, Eric Daar, Joseph de Wet, Edwin DeJesus, Jorge Del Romero Guerrero, William Dinges, Susanne Doblecki-Lewis, Taylor Donovan, Olamide Dosekun, Jason Flamm, Joel Gallant, Jan Gerstoft, Jay Gladstein, Robert Grant, Robert Grossberg, Bernhard Haas, Jason Halperin, W. David Hardy, Charles Hare, Shawn Hassler, Richard Hengel, William Henry, Theo Hodge, Sybil Hosek, Christopher Hurt, Michelle Iandiorio, Heiko Jessen, Stephen Kegg, Gabriele Knecht, Ivanka Krznaric, Anthony LaMarca, Carsten Schade Larsen, Olav Ditlevsen Larsen, Adriano Lazzarin, Clifford Leen, Christopher Lucasti, Patrick Mallon, Sharon Mannheimer, Martin Markowitz, Claudia Martorell, Kenneth Mayer, Anthony Mills, Jean-Michel Molina, Sheldon Morris, Karam Mounzer, Nneka Nwokolo, Olayemi Osiyemi, Andrew Petroll, Patrick Philibert, John Phoenix, Gilles Pialoux, Frank Post, Maria Prins, Moti Ramgopal, Bruce Rashbaum, Iain Reeves, Gary Richmond, Armin Rieger, Peter Ruane, Laura Salazar, Anthony Scarsella, Gabriel Schembri, Mia Scott, Peter Shalit, Gary Sinclair, Magdalena Sobieszczyk, Christoph Spinner, Jeffrey Stephens, Jason Szabo, Stephen Taylor, Melanie Thompson, Cecile Tremblay, Benoit Trottier, Gene Voskuhl, Barbara Wade, Kimberly Workowski, Sigal Yawetz, Benjamin Young

Publikováno v: The Lancet HIV, 8(7), e397-e407. Elsevier Limited
DISCOVER study team 2021, ' Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis : week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial ', The Lancet HIV, vol. 8, no. 7, pp. e397-e407 . https://doi.org/10.1016/S2352-3018(21)00071-0

Summary Background In DISCOVER, a multinational, randomised controlled trial, emtricitabine and tenofovir alafenamide compared with emtricitabine and tenofovir disoproxil fumarate showed non-inferior efficacy for HIV prevention and improved bone mine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::303b5922ad83d78a448781b8c096428c
https://doi.org/10.1016/s2352-3018(21)00071-0

Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure

Autor: David R. Shaw, Yang Lei, Joel Gallant, Robert Reindollar, Sarah Kopecky-Bromberg, Stephen Pianko, Maria Buti, Stanislas Pol, Jens Kort, Armen Asatryan, Michael W. Fried, Preethi Krishnan, C.-W. Lin, Stuart C. Gordon, Fred Poordad, Christophe Hézode, Federico J. Mensa, Franco Felizarta, Teresa I. Ng, David E. Bernstein

Publikováno v: Hepatology (Baltimore, Md.)

Methods: MAGELLAN-1 Part 2 was a randomized, open-label, phase 3 study to evaluate the efficacy and safety of ribavirin (RBV)-free glecaprevir and pibrentasvir (G/P; 300 mg/120 mg) in patients with chronic HCV and prior virologic failure on at least

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::134f71533e69d468f368f6e948adc780
https://doi.org/10.1002/hep.29671

Antiretroviral Therapy for the Prevention of HIV-1 Transmission

Autor: Myron S, Cohen, Ying Q, Chen, Marybeth, McCauley, Theresa, Gamble, Mina C, Hosseinipour, Nagalingeswaran, Kumarasamy, James G, Hakim, Johnstone, Kumwenda, Beatriz, Grinsztejn, Jose H S, Pilotto, Sheela V, Godbole, Suwat, Chariyalertsak, Breno R, Santos, Kenneth H, Mayer, Irving F, Hoffman, Susan H, Eshleman, Estelle, Piwowar-Manning, Leslie, Cottle, Xinyi C, Zhang, Joseph, Makhema, Lisa A, Mills, Ravindre, Panchia, Sharlaa, Faesen, Joseph, Eron, Joel, Gallant, Diane, Havlir, Susan, Swindells, Vanessa, Elharrar, David, Burns, Taha E, Taha, Karin, Nielsen-Saines, David D, Celentano, Max, Essex, Sarah E, Hudelson, Andrew D, Redd, Thomas R, Fleming, Robert, Bollinger

Publikováno v: The New England journal of medicine, vol 375, iss 9

BackgroundAn interim analysis of data from the HIV Prevention Trials Network (HPTN) 052 trial showed that antiretroviral therapy (ART) prevented more than 96% of genetically linked infections caused by human immunodeficiency virus type 1 (HIV-1) in s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9a8eed5e7e5c3962262d9d8df7d60c1
https://doi.org/10.1056/nejmoa1600693

DEAR DOCTOR... WHAT ABOUT CANCER? AND OTHER QUESTIONS ANSWERED

Autor: Joel, Gallant

Publikováno v: Positively aware : the monthly journal of the Test Positive Aware Network. 27(7)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::348e438fe8c499aba7ad6cb4011b05e8
https://pubmed.ncbi.nlm.nih.gov/27491245